BRPI0507427A - conjugados do hormÈnio de crescimento humano monopeguilados n-terminalmente, processos para o seu preparo e seus métodos de usos - Google Patents
conjugados do hormÈnio de crescimento humano monopeguilados n-terminalmente, processos para o seu preparo e seus métodos de usosInfo
- Publication number
- BRPI0507427A BRPI0507427A BRPI0507427-4A BRPI0507427A BRPI0507427A BR PI0507427 A BRPI0507427 A BR PI0507427A BR PI0507427 A BRPI0507427 A BR PI0507427A BR PI0507427 A BRPI0507427 A BR PI0507427A
- Authority
- BR
- Brazil
- Prior art keywords
- growth hormone
- human growth
- terminally
- methods
- processes
- Prior art date
Links
- 102000002265 Human Growth Hormone Human genes 0.000 title abstract 5
- 108010000521 Human Growth Hormone Proteins 0.000 title abstract 5
- 239000000854 Human Growth Hormone Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000018997 Growth Hormone Human genes 0.000 abstract 1
- 108010051696 Growth Hormone Proteins 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000003827 glycol group Chemical group 0.000 abstract 1
- 239000000122 growth hormone Substances 0.000 abstract 1
- 102000035118 modified proteins Human genes 0.000 abstract 1
- 108091005573 modified proteins Proteins 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormones [GH] (Somatotropin)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/771,895 US20040142870A1 (en) | 2002-11-20 | 2004-02-04 | N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof |
PCT/IB2005/000171 WO2005079838A1 (en) | 2004-02-04 | 2005-01-24 | N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0507427A true BRPI0507427A (pt) | 2007-06-26 |
Family
ID=34886516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0507427-4A BRPI0507427A (pt) | 2004-02-04 | 2005-01-24 | conjugados do hormÈnio de crescimento humano monopeguilados n-terminalmente, processos para o seu preparo e seus métodos de usos |
Country Status (21)
Country | Link |
---|---|
US (1) | US20040142870A1 (no) |
EP (2) | EP1915999A1 (no) |
JP (3) | JP2007520544A (no) |
KR (2) | KR100776862B1 (no) |
CN (1) | CN1929857A (no) |
AT (1) | ATE365047T1 (no) |
AU (1) | AU2005215250A1 (no) |
BR (1) | BRPI0507427A (no) |
CA (1) | CA2555772A1 (no) |
CY (1) | CY1106723T1 (no) |
DE (1) | DE602005001445T2 (no) |
DK (1) | DK1715887T3 (no) |
ES (1) | ES2286787T3 (no) |
IL (1) | IL176998A0 (no) |
NO (1) | NO20063926L (no) |
PL (1) | PL1715887T3 (no) |
PT (1) | PT1715887E (no) |
RU (1) | RU2006128293A (no) |
TW (2) | TW200812610A (no) |
WO (1) | WO2005079838A1 (no) |
ZA (2) | ZA200706349B (no) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030171285A1 (en) * | 2001-11-20 | 2003-09-11 | Finn Rory F. | Chemically-modified human growth hormone conjugates |
JP4764630B2 (ja) * | 2002-09-09 | 2011-09-07 | ネクター セラピューティックス | 水溶性ポリマーアルカナール |
AU2003263552A1 (en) * | 2002-09-09 | 2004-03-29 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
US20040142870A1 (en) * | 2002-11-20 | 2004-07-22 | Finn Rory F. | N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof |
WO2004060299A2 (en) * | 2002-12-26 | 2004-07-22 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of interferon-beta with enhanced biological potency |
RS20050501A (en) * | 2002-12-26 | 2007-08-03 | Mountain View Pharmaceuticals Inc., | Polymer conjugates of cytokines,chemokines,growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
AU2005277389A1 (en) * | 2004-08-18 | 2006-03-02 | Elixir Pharmaceuticals, Inc. | Growth-hormone secretagogues |
EP1781791A2 (en) * | 2004-08-20 | 2007-05-09 | Novo Nordisk A/S | Hemopexin fusion proteins |
US7998930B2 (en) | 2004-11-04 | 2011-08-16 | Hanall Biopharma Co., Ltd. | Modified growth hormones |
JP2008531482A (ja) * | 2005-02-10 | 2008-08-14 | ノボ ノルディスク アクティーゼルスカブ | C末端がpeg化された成長ホルモン |
US20060233740A1 (en) * | 2005-03-23 | 2006-10-19 | Bossard Mary J | Conjugates of an hGH moiety and a polymer |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
CA2627939A1 (en) * | 2005-12-15 | 2007-06-21 | Laboratoires Serono S.A. | New chemokine antagonists |
CN101495536B (zh) * | 2006-05-26 | 2012-03-07 | 益普生制药股份有限公司 | 位点特异性聚乙二醇化的方法 |
MX2010010953A (es) * | 2008-04-03 | 2011-04-21 | Biosteed Gene Expression Tech Co Ltd | Hormona de crecimiento modificada con glicol de polietileno de doble cadena, metodo de preparacion y aplicación del a misma. |
US9272048B2 (en) | 2008-04-29 | 2016-03-01 | Ascendis Pharma Growth Disorders Division A/S | PEGylated recombinant human growth hormone compounds |
EP2113256A1 (en) | 2008-04-29 | 2009-11-04 | Ascendis Pharma AS | PEGylated rhGH compounds |
UA104146C2 (ru) * | 2008-07-31 | 2014-01-10 | Фармаиссеншиа Корп. | ПОЛИМЕРНЫЕ КОНЪЮГАТЫ ФРАГМЕНТОВ ИНТЕРФЕРОНА-β, ЭРИТРОПОЭТИНА И ГОРМОНА РОСТА |
US8680050B2 (en) * | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
US8703717B2 (en) * | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
CN102348715B (zh) | 2009-02-03 | 2017-12-08 | 阿穆尼克斯运营公司 | 延伸重组多肽和包含该延伸重组多肽的组合物 |
US9849188B2 (en) | 2009-06-08 | 2017-12-26 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
WO2011018515A1 (en) * | 2009-08-14 | 2011-02-17 | Novo Nordisk Health Care Ag | Method of purifying pegylated proteins |
ES2667025T3 (es) | 2009-12-15 | 2018-05-09 | Ascendis Pharma Endocrinology Division A/S | Composición seca de hormona de crecimiento unida transitoriamente a un portador de polímero |
CN102453089B (zh) * | 2010-10-25 | 2014-06-04 | 北京凯因科技股份有限公司 | 重组集成干扰素变异体聚乙二醇偶联物的制备和应用 |
US10111933B2 (en) * | 2011-12-09 | 2018-10-30 | Metabolic Pharmaceuticals Pty Ltd | Use of growth hormone fragments |
CN102964588A (zh) * | 2012-11-09 | 2013-03-13 | 河南工业大学 | 末端连接氨基苯丙酸的聚乙二醇的酸或活性酯的制法和应用 |
KR101599415B1 (ko) | 2015-05-29 | 2016-03-03 | (주)신명이앤씨 | 건축물 층간 바닥 전기 케이블 보호관 |
CN114539384A (zh) * | 2020-11-19 | 2022-05-27 | 江苏众红生物工程创药研究院有限公司 | 聚乙二醇化长效生长激素及其制备方法和医药应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA04004809A (es) * | 2001-11-20 | 2004-08-11 | Pharmacia Corp | Conjugados de hormona de crecimiento humana modificada quimicamente. |
US20040142870A1 (en) * | 2002-11-20 | 2004-07-22 | Finn Rory F. | N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof |
-
2004
- 2004-02-04 US US10/771,895 patent/US20040142870A1/en not_active Abandoned
-
2005
- 2005-01-24 AT AT05702331T patent/ATE365047T1/de not_active IP Right Cessation
- 2005-01-24 EP EP07110559A patent/EP1915999A1/en not_active Withdrawn
- 2005-01-24 BR BRPI0507427-4A patent/BRPI0507427A/pt not_active IP Right Cessation
- 2005-01-24 DK DK05702331T patent/DK1715887T3/da active
- 2005-01-24 PT PT05702331T patent/PT1715887E/pt unknown
- 2005-01-24 DE DE602005001445T patent/DE602005001445T2/de not_active Expired - Fee Related
- 2005-01-24 EP EP05702331A patent/EP1715887B1/en active Active
- 2005-01-24 WO PCT/IB2005/000171 patent/WO2005079838A1/en active IP Right Grant
- 2005-01-24 JP JP2006551943A patent/JP2007520544A/ja active Pending
- 2005-01-24 ZA ZA200706349A patent/ZA200706349B/xx unknown
- 2005-01-24 KR KR1020067015733A patent/KR100776862B1/ko not_active IP Right Cessation
- 2005-01-24 CA CA002555772A patent/CA2555772A1/en not_active Abandoned
- 2005-01-24 CN CNA2005800073938A patent/CN1929857A/zh active Pending
- 2005-01-24 KR KR1020077007102A patent/KR20070039623A/ko not_active Application Discontinuation
- 2005-01-24 PL PL05702331T patent/PL1715887T3/pl unknown
- 2005-01-24 ES ES05702331T patent/ES2286787T3/es active Active
- 2005-01-24 AU AU2005215250A patent/AU2005215250A1/en not_active Abandoned
- 2005-01-24 RU RU2006128293/14A patent/RU2006128293A/ru not_active Application Discontinuation
- 2005-02-03 TW TW096134157A patent/TW200812610A/zh unknown
- 2005-02-03 TW TW094103308A patent/TW200529868A/zh unknown
-
2006
- 2006-07-20 IL IL176998A patent/IL176998A0/en unknown
- 2006-08-01 ZA ZA200606375A patent/ZA200606375B/xx unknown
- 2006-09-01 NO NO20063926A patent/NO20063926L/no not_active Application Discontinuation
-
2007
- 2007-07-12 CY CY20071100928T patent/CY1106723T1/el unknown
- 2007-08-15 JP JP2007211676A patent/JP2008001713A/ja not_active Withdrawn
- 2007-08-15 JP JP2007211682A patent/JP2008037872A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
TW200812610A (en) | 2008-03-16 |
US20040142870A1 (en) | 2004-07-22 |
ES2286787T3 (es) | 2007-12-01 |
EP1915999A1 (en) | 2008-04-30 |
KR20060120240A (ko) | 2006-11-24 |
DK1715887T3 (da) | 2007-09-17 |
DE602005001445T2 (de) | 2008-02-14 |
RU2006128293A (ru) | 2008-02-10 |
JP2008037872A (ja) | 2008-02-21 |
WO2005079838A1 (en) | 2005-09-01 |
IL176998A0 (en) | 2006-12-10 |
KR100776862B1 (ko) | 2007-11-28 |
JP2008001713A (ja) | 2008-01-10 |
AU2005215250A1 (en) | 2005-09-01 |
KR20070039623A (ko) | 2007-04-12 |
CN1929857A (zh) | 2007-03-14 |
PL1715887T3 (pl) | 2007-12-31 |
EP1715887A1 (en) | 2006-11-02 |
TW200529868A (en) | 2005-09-16 |
NO20063926L (no) | 2006-10-30 |
CA2555772A1 (en) | 2005-09-01 |
CY1106723T1 (el) | 2012-05-23 |
DE602005001445D1 (de) | 2007-08-02 |
ZA200606375B (en) | 2007-11-28 |
ATE365047T1 (de) | 2007-07-15 |
JP2007520544A (ja) | 2007-07-26 |
EP1715887B1 (en) | 2007-06-20 |
PT1715887E (pt) | 2007-08-29 |
ZA200706349B (en) | 2008-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0507427A (pt) | conjugados do hormÈnio de crescimento humano monopeguilados n-terminalmente, processos para o seu preparo e seus métodos de usos | |
Rink | Zinc and the immune system | |
Park et al. | Induction of HO-1 through p38 MAPK/Nrf2 signaling pathway by ethanol extract of Inula helenium L. reduces inflammation in LPS-activated RAW 264.7 cells and CLP-induced septic mice | |
ES2915851T3 (es) | Péptidos quiméricos de FGF19 para usar en el tratamiento de trastornos de ácidos biliares | |
MX344559B (es) | Compuestos de hormona de crecimiento humana recombinante unidos al peg. | |
BR0316050A (pt) | Métodos de tratar, controlar ou prevenir um câncer especìfico e doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com terapia de radiação, terapia hormonal, terapia biológica, ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit | |
AP2004003050A0 (en) | Chemically modified human growth hormone conjugates | |
Van den Boom et al. | Influence of repeated arthrocentesis and exercise on synovial fluid concentrations of nitric oxide, prostaglandin E2 and glycosaminoglycans in healthy equine joints | |
ES2395818T3 (es) | Composición que comprende un agente farmacológicamente activo acoplado a un componente específico de célula diana, y una saponina | |
BRPI0513798A (pt) | anticorpos anti-cd154 | |
AR063150A1 (es) | Formulaciones estables | |
SK328092A3 (en) | Method of improving of organoleptic properties of heat of ungelded males of domestic animals | |
Fernandez-Sanchez et al. | Nefopam, an analogue of orphenadrine, protects against both NMDA receptor-dependent and independent veratridine-induced neurotoxicity | |
CO2020004801A2 (es) | Uso de suplementos de aminoácidos para mejorar la síntesis de proteínas musculares | |
Kawase et al. | Characteristics of NaF‐induced differentiation of HL‐60 cells | |
UY28085A1 (es) | Conjugados de hormona de crecimiento humana pegilados n-terminales y proceso para su preparación | |
BRPI0607436B8 (pt) | base cristalina do composto trans-1-((1r,3s)-6-cloro-3-fenil-indan-1-il)-3,3-dimetil-piperazina, sua composição farmacêutica, seus usos, seu método de preparação, método para fabricação do referido composto, bem como base livre do referido composto | |
Hussain et al. | Piracetam attenuates binge eating disorder related symptoms in rats | |
Slotkin et al. | α7 Nicotinic acetylcholine receptors targeted by cholinergic developmental neurotoxicants: nicotine and chlorpyrifos | |
Förstermann | Regulation of nitric oxide synthase expression and activity | |
De Freitas et al. | Caffeine alters glutamate–aspartate transporter function and expression in rat retina | |
KR101459080B1 (ko) | 알부민-아밀로이드 펩타이드 컨주게이트 및 그의 용도 | |
Bourcier et al. | Synergistic interaction of interleukin‐1β and growth factors in primary cultures of rat aortic smooth muscle cells | |
ES2186596T3 (es) | Uso de inhibidores de la interleucina-18 para inhibir metastasis tumorales. | |
Lee et al. | Wild ginseng attenuates repeated morphine-induced behavioral sensitization in rats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A E 6A ANUIDADES |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011. |